92 related articles for article (PubMed ID: 22084895)
41. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products.
Zhang Y; Lave JR; Donohue JM; Fischer MA; Chernew ME; Newhouse JP
Med Care; 2010 May; 48(5):409-17. PubMed ID: 20393360
[TBL] [Abstract][Full Text] [Related]
42. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
43. Factors affecting demand among older adults for medication therapy management services.
Brooks JM; Unni EJ; Klepser DG; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2008 Dec; 4(4):309-19. PubMed ID: 19064238
[TBL] [Abstract][Full Text] [Related]
44. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
45. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
46. Medicare Part D: how do vulnerable beneficiaries fare?
Summer L; Nemore P; Finberg J
Issue Brief (Commonw Fund); 2008 Apr; 35():1-11. PubMed ID: 18536146
[TBL] [Abstract][Full Text] [Related]
47. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
48. Adverse selection in the Medicare prescription drug program.
Riley GF; Levy JM; Montgomery MA
Health Aff (Millwood); 2009; 28(6):1826-37. PubMed ID: 19887424
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
50. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.
Polinski JM; Shrank WH; Huskamp HA; Glynn RJ; Liberman JN; Schneeweiss S
PLoS Med; 2011 Aug; 8(8):e1001075. PubMed ID: 21857811
[TBL] [Abstract][Full Text] [Related]
51. Generic-only drug coverage in the Medicare Part D gap and effect on medication cost-cutting behaviors for patients with diabetes mellitus: the translating research into action for diabetes study.
Duru OK; Mangione CM; Hsu J; Steers WN; Quiter E; Turk N; Ettner SL; Schmittdiel JA; Tseng CW
J Am Geriatr Soc; 2010 May; 58(5):822-8. PubMed ID: 20406312
[TBL] [Abstract][Full Text] [Related]
52. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.
Siris ES; Yu J; Bognar K; DeKoven M; Shrestha A; Romley JA; Modi A
Clin Interv Aging; 2015; 10():1813-24. PubMed ID: 26604724
[TBL] [Abstract][Full Text] [Related]
53. Factors Associated with Entering the Prescription Drug Coverage Gap Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease.
Xu Q; Laxa SS; Serna O; Sansgiry SS
Popul Health Manag; 2021 Apr; 24(2):241-248. PubMed ID: 32343925
[TBL] [Abstract][Full Text] [Related]
54. The Impact of Coverage Restrictions on Antipsychotic Utilization Among Low-Income Medicare Part D Enrollees.
Roberto PN; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
Adm Policy Ment Health; 2017 Nov; 44(6):943-954. PubMed ID: 28660370
[TBL] [Abstract][Full Text] [Related]
55. Association between the Part D coverage gap and adverse health outcomes.
Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Christopher Roebuck M; Schneeweiss S
J Am Geriatr Soc; 2012 Aug; 60(8):1408-17. PubMed ID: 22788544
[TBL] [Abstract][Full Text] [Related]
56. Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D.
Hartung DM; Johnston KA; Irwin A; Markwardt S; Bourdette DN
Health Aff (Millwood); 2019 Feb; 38(2):303-312. PubMed ID: 30715973
[TBL] [Abstract][Full Text] [Related]
57. Entering and exiting the Medicare part D coverage gap: role of comorbidities and demographics.
Ettner SL; Steers N; Duru OK; Turk N; Quiter E; Schmittdiel J; Mangione CM
J Gen Intern Med; 2010 Jun; 25(6):568-74. PubMed ID: 20217267
[TBL] [Abstract][Full Text] [Related]
58. Medicare Part D Beneficiaries' Plan Switching Decisions and Information Processing.
Han J; Urmie J
Med Care Res Rev; 2018 Dec; 75(6):721-745. PubMed ID: 29148328
[TBL] [Abstract][Full Text] [Related]
59. Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment.
Polinski JM; Schneeweiss S; Glynn RJ; Lii J; Rassen JA
Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2(Suppl 2):90-8. PubMed ID: 22552984
[TBL] [Abstract][Full Text] [Related]
60. Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap.
Page RL; Ghushchyan V; Allen RR; Roper L; Beck D; Jonathan BH; Frech-Tamas F; Chan W; McQueen RB; Nair KV
Drug Healthc Patient Saf; 2012; 4():67-74. PubMed ID: 22826644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
